Rybrevant Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The rybrevant market research report is one of a series of new reports that provides rybrevant market statistics, including the rybrevant industry's global market size, regional shares, competitors with a rybrevant market share, detailed rybrevant market segments, market trends and opportunities, and any further data you may need to thrive in the rybrevant industry. This rybrevant market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to an increasing number of cancer patients, rising investments, a growing geriatric population, increasing demand for targeted therapies, and increasing prevalence of various types of cancers. Major trends in the forecast period include advanced healthcare infrastructure, technological development, new product launches, R&D amongst major key players, and product approvals.

The growing number of cancer patients is expected to drive the growth of the Rybrevant market. Cancer patients refer to individuals diagnosed with cancer, a group of diseases characterized by uncontrolled cell growth and spread. The increasing incidence of cancer is mainly due to an aging population, as older individuals are more susceptible to developing cancer, alongside improved diagnostic techniques that allow for better detection and reporting of cancer cases. Rybrevant is used to treat non-small cell lung cancer (NSCLC) by targeting EGFR and MET proteins, particularly in patients with EGFR exon 20 insertion mutations, to prevent tumor growth and stimulate an immune response. For example, in May 2024, the Canadian Cancer Society reported that 32,100 people in Canada were diagnosed with lung cancer in 2024, representing 23.5% of all cancer-related deaths. Notably, lung cancer diagnoses among women increased from 15,800 cases in 2023 to 17,300 in 2024. This rise in cancer patients is contributing to the growth of the Rybrevant market.

The increasing adoption of personalized medicine is expected to propel the growth of the Rybrevant market. Personalized medicine, or precision medicine, involves tailoring healthcare decisions and treatments to the specific characteristics of individual patients. This trend is driven by advancements in genomic research, enabling therapies to be based on genetic mutations, leading to better treatment efficacy, fewer side effects, and improved patient outcomes. Rybrevant contributes to personalized medicine by offering targeted therapy for non-small cell lung cancer (NSCLC) patients with genetic mutations, such as EGFR exon 20 insertion, which allows for customized treatment plans that enhance effectiveness and minimize adverse effects. For instance, the Personalized Medicine Coalition reported that in 2022, 12 new personalized medicines were approved, representing about 34% of all new therapies, a significant increase compared to previous years. As a result, the growing adoption of personalized medicines is supporting the growth of the Rybrevant market.

The key trends in the Rybrevant market is the development of innovative therapies, particularly targeted treatments for non-small cell lung cancer (NSCLC), aimed at improving treatment outcomes, addressing unmet medical needs, and boosting survival rates through precision medicine. Targeted therapies for NSCLC focus on specific molecular changes or mutations in cancer cells, aiming to stop tumor growth while reducing damage to healthy cells. For example, in March 2024, Johnson & Johnson received approval from the U.S. Food and Drug Administration (FDA) for Rybrevant (amivantamab-vmjw) as a first-line treatment for NSCLC patients with specific genetic mutations. This approval followed positive results from the Phase 3 PAPILLON study, which showed a 61% reduction in the risk of disease progression or death compared to chemotherapy alone. This approval provides a new option for patients with particular EGFR mutations, filling a critical gap in the NSCLC treatment landscape.

The key company operating in the rybrevant market is Johnson & Johnson Service Inc.

North America was the largest region in the rybrevant market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rybrevant report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rybrevant market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Rybrevant (amivantamab) is a monoclonal antibody used to treat non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. It works by targeting and inhibiting the EGFR and MET receptors to slow the growth and spread of cancer.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary clinical indications for Rybrevant include NSCLC with MET amplification, broader EGFR-mutated NSCLC, and combination therapies for advanced or metastatic NSCLC. NSCLC with MET amplification refers to a subset of NSCLC where there is an abnormal increase in the number of MET gene copies. The MET gene encodes the hepatocyte growth factor receptor (HGFR), which contributes to tumor growth, metastasis, and therapy resistance. Treatment options include first-line, second-line, and monotherapy for NSCLC with EGFR mutations. Rybrevant is administered through intravenous infusion or subcutaneous injection and is distributed via various channels, including hospitals and specialty pharmacies.

The rybrevant market consists of sales of products including targeted therapy drugs, immunotherapy drugs, chemotherapy drugs, and angiogenesis inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.